ActiTrexx GmbH

Mission & Vision: ATreg – For a life without Transplant Rejection. Graft-versus-Host-Disease (GvHD) is a common complication of stem cell transplantation that is associated with high morbidity and mortality. Our goal is to prevent the development of GvHD at an early stage with the cellular therapy ATreg and thus to provide a curative therapy with few side effects for patients with blood stem cell transplantation for the first time. ATreg is a safe and efficient treatment option for transplanted patients providing substantial improvement of survival rate and quality of life. ATreg addresses a high unmet medical need and has the potential to solve the current risks and limitations inherent with stem cell transplantation.